Ensign Peak Advisors
ROIV icon

Ensign Peak Advisors’s Roivant Sciences ROIV Stock Holding History

Ensign Peak Advisors’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.8M Sell
871,432
-147,410
-14% -$4.36M 0.05% 252
2026
Q1 		$28.2M Buy
1,018,842
+984,353
+2,854% +$25.3M 0.05% 258
2025
Q4 		$748K Sell
34,489
-20,839
-38% -$411K ﹤0.01% 865
2025
Q3 		$837K Sell
55,328
-63,050
-53% -$781K ﹤0.01% 1120
2025
Q2 		$1.33M Hold
118,378
– – ﹤0.01% 1080
2025
Q1 		$1.19M Hold
118,378
– – ﹤0.01% 1150
2024
Q4 		$1.4M Hold
118,378
– – ﹤0.01% 1117
2024
Q3 		$1.37M Hold
118,378
– – ﹤0.01% 1139
2024
Q2 		$1.25M Hold
118,378
– – ﹤0.01% 1144
2024
Q1 		$1.25M Sell
118,378
-731,472
-86% -$7.89M ﹤0.01% 1173
2023
Q4 		$9.54M Hold
849,850
– – 0.02% 452
2023
Q3 		$9.93M Buy
849,850
+738,150
+661% +$8.34M 0.02% 394
2023
Q2 		$1.13M Buy
111,700
+1,450
+1% +$13K ﹤0.01% 1166
2023
Q1 		$814K Hold
110,250
– – ﹤0.01% 1414
2022
Q4 		$881K Buy
110,250
+74,650
+210% +$415K ﹤0.01% 1262
2022
Q3 		$115K Buy
+35,600
New +$138K ﹤0.01% 2055

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Ensign Peak Advisors's ROIV Position: Q2 2026 in Review

Ensign Peak Advisors reduced its Roivant Sciences (ROIV) stake by 14% in Q2 2026, selling an estimated $4.36M and leaving 871,432 shares worth $30.8M. The position accounts for 0.05% of the portfolio, ranked #252.

Ensign Peak Advisors first reported a position in ROIV in Q3 2022 and has held it in 16 quarters since. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • Ensign Peak Advisors held 871,432 shares of Roivant Sciences worth $30.8M as of Q2 2026.
  • Ensign Peak Advisors sold 147,410 Roivant Sciences shares in Q2 2026, an estimated $4.36M.
  • Roivant Sciences made up 0.05% of Ensign Peak Advisors's portfolio in Q2 2026, its #252 holding.
  • Ensign Peak Advisors first reported a position in Roivant Sciences in Q3 2022 and has held it in 16 quarters since.
  • 498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.